Vitamin K2 treatment for postmenopausal osteoporosis in Indonesia

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

To investigate the effect of vitamin K2 (menatetrenone) treatment on bone mineral density (BMD) and a bone metabolic marker (osteocalcin) in postmenopausal women with osteoporosis living in Indonesia.

Who Took Part

The study group was 63 women.

By PubMed's age tags, the people studied were middle-aged adults and older adults, women only.

A double-blind randomized placebo-controlled study of 63 postmenopausal women with osteoporosis.

BMD of lumbal spine (L2-L4), osteocalcin (OC) and undercarboxylated OC were measured before, 24 and 48 weeks after initiation of the treatment.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The women were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Neither the women nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

Some women received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

What Was Measured

The subject headings attached to it are Bone Density, Indonesia, Osteocalcin, Osteoporosis, Postmenopausal and Vitamin K 2.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 63 women.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2006 (The journal of obstetrics and gynaecology research), a journal based in Australia.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.